Literature DB >> 2695333

Vascular control by purines with emphasis on the coronary system.

G Burnstock1.   

Abstract

There is growing evidence for several different roles for purines in the control of blood flow. (1) Adenosine 5'-triphosphate (ATP) acts as a cotransmitter with noradrenaline and neuropeptide Y released from sympathetic perivascular nerves. In most vessels it acts via P2x-purinoceptors to produce vasoconstriction synergistically with alpha-adrenoceptor activation, while in some coronary vessels it appears to act via P2Y-purinoceptors to produce vasodilatation in concert with beta-adrenoceptor activation. (2) Adenosine, via P1-purinoceptors, acts as a prejunctional modulator of transmitter release from perivascular nerves; it also acts directly on vascular smooth muscle to produce vasodilatation. (3) ATP is stored in and released from vascular endothelial cells (including those from the coronary bed) during changes in blood flow or during hypoxia, and acts via P2Y-purinoceptors on endothelial cells to release endothelium-derived relaxing factor, resulting in vasodilatation. (4) ATP may be released together with substance P and calcitonin gene-related peptide from some sensory nerves during 'axon-reflex' activity when antidromic impulses pass down collaterals supplying blood vessels. (5) Finally, there is evidence to suggest that ATP released from intrinsic (non-sympathetic) neurones in the airways and heart has potent actions on the resistance vessels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695333     DOI: 10.1093/eurheartj/10.suppl_f.15

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

1.  Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat.

Authors:  P G Green; A I Basbaum; C Helms; J D Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

Review 2.  Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.

Authors:  Iain L O Buxton; Nucharee Yokdang; Robert M Matz
Journal:  Cancer Lett       Date:  2010-05-28       Impact factor: 8.679

Review 3.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

4.  The effects of purine compounds on the isolated aorta of the frog Rana temporaria.

Authors:  G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

5.  Contribution of adenosine to the depression of sympathetically evoked vasoconstriction induced by systemic hypoxia in the rat.

Authors:  Andrew M Coney; Janice M Marshall
Journal:  J Physiol       Date:  2003-04-17       Impact factor: 5.182

6.  The stable pyrimidines UDPbetaS and UTPgammaS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery.

Authors:  M Malmsjö; M Adner; T K Harden; W Pendergast; L Edvinsson; D Erlinge
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

7.  Hypoxic vasodilatation in isolated, perfused guinea-pig heart: an analysis of the underlying mechanisms.

Authors:  N von Beckerath; S Cyrys; A Dischner; J Daut
Journal:  J Physiol       Date:  1991-10       Impact factor: 5.182

8.  Endothelium-dependent relaxation and endothelial hyperpolarization by P2Y receptor agonists in rat-isolated mesenteric artery.

Authors:  Hammit Mistry; Jonathan M Gitlin; Jane A Mitchell; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 9.  Endothelial vasomotor regulation in health and disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

10.  Inhibition of hypoxia-induced relaxation of rabbit isolated coronary arteries by NG-monomethyl-L-arginine but not glibenclamide.

Authors:  C Jiang; P Collins
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.